STOCK TITAN

Disc Medicine Inc SEC Filings

IRON NASDAQ

Welcome to our dedicated page for Disc Medicine SEC filings (Ticker: IRON), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.

Disc Medicine filings document the regulatory and financial record of a clinical-stage biopharmaceutical company developing hematologic disease therapies. Its Form 8-K disclosures cover quarterly and annual financial results, corporate updates, clinical-program materials for bitopertin, DISC-0974 and DISC-3405, and FDA communications related to the bitopertin New Drug Application for erythropoietic protoporphyria.

The filing record also includes proxy materials covering board matters, executive compensation and shareholder voting items. Material-event reports describe Regulation FD presentations, operating runway disclosures, restructuring actions following regulatory developments, and risk-related statements around clinical trials, regulatory pathways, research spending and capital resources.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
-
Rhea-AI Summary

Disc Medicine, Inc. (NASDAQ: IRON) – Form 4 insider transaction

Chief Financial Officer Jean M. Franchi filed a Form 4 reporting the sale of 2,000 shares of common stock on 16 June 2025. The shares were sold under a previously adopted Rule 10b5-1 trading plan dated 10 March 2025 at a weighted-average price of $52.2594 per share, with individual trades executed between $51.79 and $52.61. Following the sale, Franchi’s direct beneficial ownership stands at 67,530 common shares.

No derivative securities were reported in this filing, and there were no acquisitions of additional shares or option exercises. The filing confirms that the transaction was executed directly (ownership code “D”).

The disposal represents roughly 3% of the reporting person’s post-transaction holdings and does not materially affect the company’s share count. While investors track Form 4 filings to assess insider sentiment, the modest size and pre-planned nature of this sale limit its informational weight.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider

FAQ

How many Disc Medicine (IRON) SEC filings are available on StockTitan?

StockTitan tracks 93 SEC filings for Disc Medicine (IRON), including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and Form 4 insider trading disclosures. Each filing includes AI-generated summaries, impact scoring, and sentiment analysis.

When was the most recent SEC filing for Disc Medicine (IRON)?

The most recent SEC filing for Disc Medicine (IRON) was filed on July 1, 2025.